This Stock is could Disrupt the Market

Nearly 1 in 3 deaths in the USA are caused by heart disease and stroke. Of the approximately 1.5 million people suffering heart attacks annually in the U.S., more than 250,000 will die within one hour of their incident. Unfortunately, for up to 50% of these individuals, the FIRST SYMPTOM of coronary artery disease is sudden cardiac death, or a heart attack.

Lexington Biosciences, Inc. (OTC: LXGTF) aims to provide the solution to early detection by introducing HEARTSENTRY, a revolutionary, simple and effective technology for personalized measurement and monitoring of vascular health to detect the potential for cardiovascular disease at its earliest stages. HEARTSENTRY is designed to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of heart attacks and stroke.

Leave a Reply

Your email address will not be published. Required fields are marked *

nine − nine =